In a nutshell This phase 1b trial is examining the effectiveness and safety of cibisatamab in combination with atezolizumab (Tecentriq) after treatment with obinutuzumab (Gazyva) in patients with previously treated metastatic colorectal carcinoma (mCRC). The main outcomes to be measured will be side effects and...
Read MoreCurrent treatment status-Not currently treated Posts on Medivizor
Evaluating brentuximab vedotin plus high-dose bendamustine for relapsed or unresponsive Hodgkin lymphoma
In a nutshell This study examined how well brentuximab vedotin (Adcetris) plus high-dose bendamustine (Treanda) worked in patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL). This study concluded that this regimen was highly effective for these patients. Some background After initial treatment, many patients with cHL...
Read MoreLooking for participants with advanced colorectal cancer to test a new targeted treatment with DS-8201a
In a nutshell This phase 2 trial is examining the effectiveness and safety of DS-8201a in the treatment of advanced HER2 positive colorectal cancer. The main outcome to be measured is the tumor response to the treatment and side effects. The details The standard treatment to advanced colorectal cancers is surgery, chemotherapy and radiation...
Read MoreChemotherapy regimens for patients with relapsed or unresponsive acute myeloid leukemia
In a nutshell This study aimed to compare outcomes of fludarabine–treosulfan (FT), thiotepa–busulfan–fludarabine (TBF), and fludarabine, Ara-C, amsacrine, total body irradiation/busulfan, cyclophosphamide (FLAMSA) in the treatment of patients with relapsed or unresponsive acute myeloid leukemia (AML). The study found that all...
Read MoreEvaluating rituximab plus lenalidomide for recurrent or non-responsive indolent non-Hodgkin lymphoma
In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with recurrent or non-responsive non-Hodgkin’s lymphoma (NHL). This study concluded that lenalidomide was well-tolerated and improved the effectiveness of rituximab in these patients. Some background Follicular...
Read MoreEvaluating pembrolizumab versus platinum-based chemotherapy for advanced NSCLC
In a nutshell This study evaluated the effectiveness of pembrolizumab (Keytruda) versus platinum-based chemotherapy for patients with non-small cell lung cancer (NSCLC). This study found that pembrolizumab treatment resulted in longer overall survival than treatment with platinum-based chemotherapy. Some background NSCLC is the...
Read MoreSearching for patients to try a new combination of treatments for relapsed or unresponsive Hodgkin lymphoma.
In a nutshell This study will investigate the effects of pembrolizumab (Keytruda) and targeted radiation therapy for relapsed or unresponsive Hodgkin lymphoma (HL). This study will measure the rate of complete response (disappearance of all cancer). The details Many patients are cured with treatments for HL. Some patients lose response to...
Read MoreOptimal treatment for relapsed and unresponsive nodular lymphocyte-predominant Hodgkin lymphoma
In a nutshell This study aimed to investigate treatments and outcomes for patients with relapsed or unresponsive nodular lymphocyte-predominant Hodgkin lymphoma. This study concluded that these patients have a good overall prognosis and treatments should be chosen individually. Some background Radiotherapy (RT), chemotherapy (CT) and rituximab...
Read MoreSearching for patients to try a combination treatment for multiple myeloma.
In a nutshell The study will investigate the effects of carfilzomib (Kyprolis), pomalidomide (Pomalyst), and dexamethasone (Decadron) in multiple myeloma (MM). The main outcome that will be measured will be the percentage of patients who have no signs or symptoms of MM after treatment (completed response). This study is recruiting in Georgia, Unites...
Read MoreNew treatment improves tumor response in patients with HER2 positive metastatic colorectal cancer
In a nutshell This study investigated the effectiveness of pertuzumab (Perjeta) and trastuzumab (Herceptin) in patients with colorectal cancer and HER2 mutation (an abnormal gene). Researchers suggested that this treatment could be a safe option for patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Some background...
Read MoreComparing conditioning regimens before stem cell transplantation for patients with Hodgkin lymphoma
In a nutshell This study evaluated the safety and effectiveness of two chemotherapy regimens before autologous stem cell transplantation (ASCT) for patients with Hodgkin lymphoma (HL). This study concluded that BEAM conditioning before ASCT significantly improved the outcomes of these patients. Some background About 20 – 30% of patients...
Read MoreThe impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant
In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads...
Read More
